Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bennett Levitan

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Clinical Ophthalmology (Auckland, N.Z.)|June 15, 2026
US Retina Specialists' Preferences for Geographic Atrophy TreatmentKarl Csaky, Anthony M Pepio, Caitlin Thomas, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 2, 2023
Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task ForceTommi Tervonen, Jorien Veldwijk, Katherine Payne, et al.
Pharmacoepidemiology and Drug Safety|October 13, 2015
Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologistChristine Radawski, Elaine Morrato, Kenneth Hornbuckle, et al.
Journal of the American College of Cardiology|July 7, 2018
Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary SyndromeC Michael Gibson, Bennett Levitan, William J Gibson, et al.
Vascular Health and Risk Management|April 8, 2014
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplastyBennett Levitan, Zhong Yuan, Alexander G G Turpie, et al.
Drug Discovery Today|May 12, 2019
Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature reviewVikas Soekhai, Chiara Whichello, Bennett Levitan, et al.
Drug Discovery Today|September 30, 2018
Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature reviewEline van Overbeeke, Chiara Whichello, Rosanne Janssens, et al.
Journal of Medical Economics|February 23, 2018
Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety resultsPhilip S Wells, Anthonie W A Lensing, Lloyd Haskell, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 21, 2019
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN StudyAlex C Spyropoulos, Concetta Lipardi, Jianfeng Xu, et al.
The Patient|July 3, 2025
Developing Tools for the Efficient Design of Health Preference Studies: Taxonomy of Attributes and Prototype of an Attribute LibraryNorah L Crossnohere, Jonah Golder, Esther W de Bekker-Grob, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Clinical Ophthalmology (Auckland, N.Z.)|June 15, 2026
US Retina Specialists' Preferences for Geographic Atrophy TreatmentKarl Csaky, Anthony M Pepio, Caitlin Thomas, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 2, 2023
Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task ForceTommi Tervonen, Jorien Veldwijk, Katherine Payne, et al.
Pharmacoepidemiology and Drug Safety|October 13, 2015
Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologistChristine Radawski, Elaine Morrato, Kenneth Hornbuckle, et al.
Journal of the American College of Cardiology|July 7, 2018
Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary SyndromeC Michael Gibson, Bennett Levitan, William J Gibson, et al.
Vascular Health and Risk Management|April 8, 2014
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplastyBennett Levitan, Zhong Yuan, Alexander G G Turpie, et al.
Drug Discovery Today|May 12, 2019
Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature reviewVikas Soekhai, Chiara Whichello, Bennett Levitan, et al.
Drug Discovery Today|September 30, 2018
Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature reviewEline van Overbeeke, Chiara Whichello, Rosanne Janssens, et al.
Journal of Medical Economics|February 23, 2018
Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety resultsPhilip S Wells, Anthonie W A Lensing, Lloyd Haskell, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 21, 2019
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN StudyAlex C Spyropoulos, Concetta Lipardi, Jianfeng Xu, et al.
The Patient|July 3, 2025
Developing Tools for the Efficient Design of Health Preference Studies: Taxonomy of Attributes and Prototype of an Attribute LibraryNorah L Crossnohere, Jonah Golder, Esther W de Bekker-Grob, et al.
Pageof 6